Starpharma’s VivaGelR patent approved in Japan
Today keynote speaker Congresswoman Nita Lowey (NY-18) joined with experts from New York Presbyterian Hospital; the Skin Cancer Foundation; 2006 Miss Maryland, a skin cancer survivor; Fallene LTD, and Ciba Corporation to call on the Food and Drug Administration (FDA) to address the dramatic rise in skin cancer rates in the United States. The panel
Full Post: Experts call for FDA to address dramatic rise in skin cancer rates in the U.S.
Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.
This approval means that VivaGel and the VivaGel coated condom are now covered by granted patents in all major markets including Europe, the US and Japan.
Last month Starpharma announced a full licence agreement with SSL International plc (LSE:SSL) in relation to the VivaGel coated condom, with estimated receipts in excess of A$100m comprising royalties, milestone payments and development support. In addition Starpharma is continuing to develop VivaGel as a stand-alone product for use by women to protect themselves from HIV and HSV-2 (genital herpes). The development for these two indications has significant NIH support.
Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company’s lead pharmaceutical development product is VivaGel (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.
SPL has a comprehensive IP portfolio with around 200 patents granted and applications pending - a unique level of IP concentration among nanotechnology companies.
Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.
Angiogenesis, the growth of new blood vessels, plays a critical role in several chronic human diseases, including metastatic cancer. In fact, several new anticancer therapies are designed to starve tumors by shutting down angiogenesis, but the lack of a good assay for quantifying angiogenesis in the body has hampered the development of effective antiangiogenesis therapies.
Full Post: Biodegradable nanoprobe images new blood vessel growth
PDL BioPharma, Inc. and Alexion Pharmaceuticals, Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion’s humanized antibody, Soliris (eculizumab) and PDL’s patents known as the Queen et al. patents. Under the agreements announced today, PDL has granted
Full Post: PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute
Mylan Inc. has announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company’s Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment. U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This
Full Post: Dey L.P. issued new U.S. patents for Perforomist inhalation solution
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United
Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva’s acquisition of Barr. In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product
Full Post: Teva and Barr receive European approval for acquisition